Huntington's disease biomarkers and therapeutics

亨廷顿病的生物标志物和治疗方法

• 批准号: 8631580
• 负责人: Wenzhen Duan
• 金额: $ 42.42万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-30 至 2018-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8631580
• 关键词: Agonist; Biological Markers; Brain; Cell model; Clinical; Clinical Research; Clinical Trials; Corpus striatum structure; Creatine; Data; Detection; Development; Disease; Disease Progression; Drug Kinetics; Equilibrium; Functional disorder; Future; Gene Mutation; Glutamates; Goals; Huntington Disease; Impairment; Knock-in Mouse; Length; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Measures; Medical; Molecular; Monitor; Mus; N-acetylaspartate; Nerve Degeneration; Neurodegenerative Disorders; Neuronal Dysfunction; Neurons; Outcome Measure; Pharmacodynamics; Phase; Research; Structure-Activity Relationship; Testing; Therapeutic; Therapeutic Agents; Toxic effect; Treatment Efficacy; Validation; analog; base; cerebral atrophy; design; efficacy trial; functional disability; gamma-Aminobutyric Acid; human Huntingtin protein; in vivo; mouse model; mutant; neuroimaging; neuronal circuitry; pre-clinical; preclinical efficacy; preclinical study; prevent; protective effect; public health relevance; response; small molecule

DESCRIPTION (provided by applicant): Huntington's disease (HD) is a devastating neurodegenerative disorder caused by mutation of the gene huntingtin. No treatment prevented or slowed disease progression. To develop such a treatment requires objective measures of disease progression. Neuroimaging measures provide unbiased detection of disease progression. The key issues are whether these measures truly reflect the reduction or dysfunction of medium spiny neurons - the nerve cells that selectively die in HD, and whether the neuroimaging measures correlate with other clinical features; more important is whether these measures respond to treatment sensitively and reliably. We propose employing two non-invasive longitudinal neuroimaging measures reflecting different features of the neurons, in vivo structural magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS), to determine if these measures provide the sensitive and faithful reflection of the therapeutic efficacy, and how these non-invasive measures correlate with mutant huntingtin-induced functional impairment in the full-length huntingtin knock-in mouse model. In Specific Aim 1, we will validate structural MRI measures as biomarkers and determine their response to neuroprotective treatment in full-length huntingtin knock-in mice. We will determine the correlation between MRI measures and functional impairment in HdhQ250 mice with or without treatment. In Specific Aim 2, we will investigate brain metabolite alterations in parallel with disease progression and determine whether these metabolites respond to neuroprotective treatment by use of magnetic resonance spectroscopy in full-length huntingtin knock-in mice. We hypothesize that alterations of striatal metabolites reflects early neuronal dysfunction and impairment of neuronal circuitry. We will determine if these altered metabolites respond to neuroprotective treatment, and what are the relationships between brain metabolite alterations and functional consequences of mutant huntingtin in the full- length huntingtin knock-in mice. In Specific Aim 3, we will identify clinical candidate small molecule TrkB agonist(s) by using HD cell models and further assess preclinical efficacy, pharmacokinetics, pharmacodynamics, toxicity, as well as mechanisms for promising candidate compound(s) in the full-length huntingtin knock-in mouse model. We will investigate the structure-activity relationship of newly synthesized analogs of 7,8-dihydroxyflavone in HD cell models. The promising candidate compound(s) will be further evaluated for therapeutic efficacy, pharmacokinetics, pharmacodynamics, and toxicity, as well as molecular mechanisms in the full-length huntingtin knock-in mouse model. The ultimate goal of the proposed research is to validate structural MRI and MRS as biomarkers for efficacy trials and prepare therapeutic candidate compounds for HD clinical trials.

描述（申请人提供）：亨廷顿病（HD）是一种由亨廷顿基因突变引起的破坏性神经退行性疾病。没有任何治疗可以阻止或减缓疾病进展。要开发这种治疗方法，需要对疾病进展进行客观测量。神经影像学测量提供了对疾病进展的无偏倚检测。关键问题是这些措施是否真正反映了中等多刺神经元的减少或功能障碍-在HD中选择性死亡的神经细胞，以及神经影像学措施是否与其他临床特征相关;更重要的是这些措施是否对治疗敏感可靠。我们建议采用两种非侵入性的纵向神经影像学措施，反映不同的功能的神经元，在体内结构磁共振成像（MRI）和磁共振波谱（MRS），以确定这些措施是否提供了敏感和忠实的反映治疗效果，以及这些非侵入性措施如何与突变亨廷顿蛋白诱导的功能障碍在全长亨廷顿基因敲入小鼠模型。在具体目标1中，我们将验证结构MRI测量作为生物标志物，并确定它们对全长亨廷顿基因敲入小鼠神经保护治疗的反应。我们将确定MRI测量结果与HdhQ 250小鼠（有或无治疗）功能障碍之间的相关性。在特定目标2中，我们将研究与疾病进展平行的脑代谢物改变，并通过在全长亨廷顿基因敲入小鼠中使用磁共振波谱来确定这些代谢物是否对神经保护治疗有反应。我们推测纹状体代谢物的改变反映了早期神经元功能障碍和神经元回路受损。我们将确定这些改变的代谢物是否对神经保护治疗有反应，以及在全长亨廷顿基因敲入小鼠中，脑代谢物改变与突变亨廷顿蛋白的功能后果之间的关系。在具体目标3中，我们将通过使用HD细胞模型鉴定临床候选小分子TrkB激动剂，并进一步评估全长亨廷顿基因敲入小鼠模型中有前景的候选化合物的临床前功效、药代动力学、药效学、毒性以及机制。我们将在HD细胞模型中研究新合成的7，8-二羟基黄酮类似物的构效关系。将在全长亨廷顿基因敲入小鼠模型中进一步评价有前景的候选化合物的治疗功效、药代动力学、药效学和毒性以及分子机制。拟议研究的最终目标是验证结构MRI和MRS作为疗效试验的生物标志物，并为HD临床试验制备治疗候选化合物。